<SEC-DOCUMENT>0001104659-20-076465.txt : 20200624 <SEC-HEADER>0001104659-20-076465.hdr.sgml : 20200624 <ACCEPTANCE-DATETIME>20200624164947 ACCESSION NUMBER: 0001104659-20-076465 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200623 FILED AS OF DATE: 20200624 DATE AS OF CHANGE: 20200624 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Herman Philip Karl CENTRAL INDEX KEY: 0001799303 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38650 FILM NUMBER: 20986146 MAIL ADDRESS: STREET 1: C/O Y-MABS THERAPEUTICS, INC. STREET 2: 230 PARK AVENUE, SUITE 3350 CITY: NEW YORK STATE: NY ZIP: 10169 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Y-mAbs Therapeutics, Inc. CENTRAL INDEX KEY: 0001722964 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 474619612 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 750 THIRD AVENUE STREET 2: 9TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 212-847-9841 MAIL ADDRESS: STREET 1: 750 THIRD AVENUE STREET 2: 9TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10017 </SEC-HEADER> <DOCUMENT> <TYPE>4 <SEQUENCE>1 <FILENAME>a4.xml <DESCRIPTION>4 <TEXT> <XML> <?xml version="1.0"?> <ownershipDocument> <schemaVersion>X0306</schemaVersion> <documentType>4</documentType> <periodOfReport>2020-06-23</periodOfReport> <notSubjectToSection16>0</notSubjectToSection16> <issuer> <issuerCik>0001722964</issuerCik> <issuerName>Y-mAbs Therapeutics, Inc.</issuerName> <issuerTradingSymbol>YMAB</issuerTradingSymbol> </issuer> <reportingOwner> <reportingOwnerId> <rptOwnerCik>0001799303</rptOwnerCik> <rptOwnerName>Herman Philip Karl</rptOwnerName> </reportingOwnerId> <reportingOwnerAddress> <rptOwnerStreet1>C/O Y-MABS THERAPEUTICS, INC.</rptOwnerStreet1> <rptOwnerStreet2>230 PARK AVENUE SUITE 3350</rptOwnerStreet2> <rptOwnerCity>NEW YORK</rptOwnerCity> <rptOwnerState>NY</rptOwnerState> <rptOwnerZipCode>10169</rptOwnerZipCode> <rptOwnerStateDescription></rptOwnerStateDescription> </reportingOwnerAddress> <reportingOwnerRelationship> <isDirector>0</isDirector> <isOfficer>1</isOfficer> <isTenPercentOwner>0</isTenPercentOwner> <isOther>0</isOther> <officerTitle>SVP & CCO</officerTitle> </reportingOwnerRelationship> </reportingOwner> <derivativeTable> <derivativeTransaction> <securityTitle> <value>Employee Stock Option (right to buy)</value> <footnoteId id="F1"/> </securityTitle> <conversionOrExercisePrice> <value>48.67</value> </conversionOrExercisePrice> <transactionDate> <value>2020-06-23</value> </transactionDate> <transactionCoding> <transactionFormType>4</transactionFormType> <transactionCode>A</transactionCode> <equitySwapInvolved>0</equitySwapInvolved> </transactionCoding> <transactionTimeliness> <value></value> </transactionTimeliness> <transactionAmounts> <transactionShares> <value>20000</value> </transactionShares> <transactionPricePerShare> <value>0</value> </transactionPricePerShare> <transactionAcquiredDisposedCode> <value>A</value> </transactionAcquiredDisposedCode> </transactionAmounts> <exerciseDate> <footnoteId id="F2"/> </exerciseDate> <expirationDate> <value>2030-06-23</value> </expirationDate> <underlyingSecurity> <underlyingSecurityTitle> <value>Common stock</value> </underlyingSecurityTitle> <underlyingSecurityShares> <value>20000</value> </underlyingSecurityShares> </underlyingSecurity> <postTransactionAmounts> <sharesOwnedFollowingTransaction> <value>20000</value> </sharesOwnedFollowingTransaction> </postTransactionAmounts> <ownershipNature> <directOrIndirectOwnership> <value>D</value> </directOrIndirectOwnership> </ownershipNature> </derivativeTransaction> </derivativeTable> <footnotes> <footnote id="F1">Stock options granted to the Reporting Person pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc.</footnote> <footnote id="F2">The stock option shall vest and become exercisable as to 25% of the shares subject to the option on June 23, 2021, and thereafter vests and become exercisable as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.</footnote> </footnotes> <ownerSignature> <signatureName>/s/ Philip Karl Herman</signatureName> <signatureDate>2020-06-24</signatureDate> </ownerSignature> </ownershipDocument> </XML> </TEXT> </DOCUMENT> </SEC-DOCUMENT>